Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

indomethacin embryofetopathy - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

indomethacin embryofetopathy

MONDO:0016005

Also known as:fetal indomethacin syndromefoetal indomethacin syndromeantenatal indomethacin exposure

Overview

Indomethacin embryofetopathy refers to the manifestations that may be observed in a fetus or newborn when the mother has taken indomethacin, a potent prostaglandin inhibitor and tocolytic agent that can cross placenta, during pregnancy. Reported adverse fetal/neonatal effects include decreased renal function resulting in oligohydramnios, closure of the ductus arteriosus, and delayed cardiovascular adaptation at birth. These effects are usually transient and reversible. Indomethacin may also be a risk factor for cerebral injury (periventricular leukomalacia) and necrotizing enterocolitisin preterm infants.

ResearchLimited published research (3 articles)

Prognosis

Estimated prevalence: Unknown (Unknown prevalence).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for indomethacin embryofetopathy.

3 publications have been identified in PubMed for indomethacin embryofetopathy. Research spans Review / Meta-Analysis (33%), Clinical Trial Publication (33%), and Epidemiology / Natural History (33%).

Recent Publications

Sahussarungsi S (2025). [PMID: 40722815](https://pubmed.ncbi.nlm.nih.gov/40722815/). *Biomedicines*. [Review / Meta-Analysis]
Xu C (2025). [PMID: 40374643](https://pubmed.ncbi.nlm.nih.gov/40374643/). *Sci Rep*. [Epidemiology / Natural History]
Tachihara M (2025). [PMID: 41388234](https://pubmed.ncbi.nlm.nih.gov/41388234/). *J Obstet Gynaecol Res*. [Clinical Trial Publication]

Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 11:12 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:1909

Questions for Your Care Team

→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

indomethacin embryofetopathy

Overview

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

Orphanet

Related Diseases

Questions for Your Care Team

Questions for Your Care Team